{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:11:31Z","timestamp":1779163891442,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18dm0307003h0001"],"award-info":[{"award-number":["18dm0307003h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12149-025-02051-6","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:49:30Z","timestamp":1745628570000},"page":"799-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-\u03b2 load"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0265-5636","authenticated-orcid":false,"given":"Ryo","family":"Yamakuni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunari","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Ukon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumasa","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukatsu","family":"Sawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Narumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hanakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Parkinson\u2019s and Alzheimer\u2019s disease Dimensional Neuroimaging Initiative (PADNI)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"2051_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"2051_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"2051_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-023-00473-w","volume":"12","author":"AA Tahami Monfared","year":"2023","unstructured":"Tahami Monfared AA, Ye W, Sardesai A, Folse H, Chavan A, Aruffo E, et al. A path to improved Alzheimer\u2019s care: simulating long-term health outcomes of lecanemab in early Alzheimer\u2019s disease from the CLARITY AD Trial. Neurol Ther. 2023;12:863\u201381.","journal-title":"Neurol Ther"},{"key":"2051_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, Cheng Y-J, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8:414\u201324.","journal-title":"J Prev Alzheimers Dis"},{"key":"2051_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3233\/JAD-131979","volume":"43","author":"V Tryputsen","year":"2015","unstructured":"Tryputsen V, Dibernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N. Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials. J Alzheimer\u2019s Dis. 2015;43:809\u201321.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2051_CR6","doi-asserted-by":"crossref","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.e1\u20134.","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"2051_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2967\/jnumed.117.194720","volume":"59","author":"A Whittington","year":"2018","unstructured":"Whittington A, Sharp DJ, Gunn RN. Spatiotemporal distribution of B-Amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J Nucl Med. 2018;59:822\u20137.","journal-title":"J Nucl Med"},{"key":"2051_CR8","doi-asserted-by":"crossref","unstructured":"Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand\u2019Maison M, O\u2019Neill P, et al. Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1B PRIME study of aducanumab. Journal of Nuclear Medicine. 2019;60:100\u20136.","DOI":"10.2967\/jnumed.118.209130"},{"key":"2051_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12149-023-01824-1","volume":"37","author":"YJ Jeong","year":"2023","unstructured":"Jeong YJ, Yoon HJ, Kang D-Y, Park KW. Quantitative comparative analysis of amyloid PET images using three radiopharmaceuticals. Ann Nucl Med. 2023;37:271\u20139.","journal-title":"Ann Nucl Med"},{"key":"2051_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1053\/j.semnuclmed.2020.12.005","volume":"51","author":"N Krishnadas","year":"2021","unstructured":"Krishnadas N, Villemagne VL, Dor\u00e9 V, Rowe CC. Advances in brain amyloid imaging. Semin Nucl Med. 2021;51:241\u201352.","journal-title":"Semin Nucl Med"},{"key":"2051_CR11","doi-asserted-by":"crossref","unstructured":"Rizzo G, Whittington A, Hesterman J, Gunn RN. Amyloid IQ\u202f: An advanced analytical algorithm to quantify amyloid\u2010PET [18F]NAV4694 scans. Alzheimer\u2019s & Dementia. 2020;16.","DOI":"10.1002\/alz.043823"},{"key":"2051_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.118.210518","volume":"60","author":"A Whittington","year":"2019","unstructured":"Whittington A, Gunn RN. Amyloid load: A more sensitive biomarker for amyloid imaging. J Nucl Med. 2019;60:536\u201340.","journal-title":"J Nucl Med"},{"key":"2051_CR13","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","volume":"48","author":"M Bucci","year":"2021","unstructured":"Bucci M, Savitcheva I, Farrar G, Salvad\u00f3 G, Collij L, Dor\u00e9 V, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48:2183\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2051_CR14","volume":"17","author":"K Yoshinaga","year":"2025","unstructured":"Yoshinaga K, Matsushima T, Abe M, Takamura T, Togo H, Wakasugi N, et al. Age-disproportionate atrophy in Alzheimer\u2019s disease and Parkinson\u2019s disease spectra. Alzheimers Dement. 2025;17: e70048.","journal-title":"Alzheimers Dement"},{"key":"2051_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566\u201372.","journal-title":"Br J Psychiatry"},{"key":"2051_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"2051_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"2051_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.2499","volume":"12","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Yamao T. Software development for quantitative analysis of brain amyloid PET. Brain Behav. 2022;12:1\u201310.","journal-title":"Brain Behav"},{"key":"2051_CR19","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1002\/alz.13761","volume":"20","author":"A Bollack","year":"2024","unstructured":"Bollack A, Collij LE, Garc\u00eda DV, Shekari M, Altomare D, Payoux P, et al. Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study. Alzheimers Dement. 2024;20:3429\u201341.","journal-title":"Alzheimers Dement"},{"key":"2051_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1096\/fasebj.1.5.3315805","volume":"1","author":"HJ Motulsky","year":"1987","unstructured":"Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987;1:365\u201374.","journal-title":"FASEB J"},{"key":"2051_CR21","doi-asserted-by":"crossref","unstructured":"Reynolds D. Gaussian Mixture Models. Encyclopedia of Biometrics. Boston, MA: Springer US; 2009. p. 659\u201363.","DOI":"10.1007\/978-0-387-73003-5_196"},{"key":"2051_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jss.2004.02.008","volume":"119","author":"EH Livingston","year":"2004","unstructured":"Livingston EH. The mean and standard deviation: what does it all mean? J Surg Res. 2004;119:117\u201323.","journal-title":"J Surg Res"},{"key":"2051_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/bimj.200710415","volume":"50","author":"MD Ruopp","year":"2008","unstructured":"Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 2008;50:419\u201330.","journal-title":"Biom J"},{"key":"2051_CR24","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2051_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"2051_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:22.","journal-title":"Alzheimers Res Ther"},{"key":"2051_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/alz.044786","volume":"16","author":"S Bullich","year":"2020","unstructured":"Bullich S, Salvad\u00f3 G, Alves IL, Marqui\u00e9 M, Stephens AW, Gispert JD, et al. Converging evidence for a \u201cgray-zone\u201d of amyloid burden and its relevance. Alzheimer\u2019s Dement. 2020;16:16\u20137.","journal-title":"Alzheimer\u2019s Dement."},{"key":"2051_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00807-6","volume":"13","author":"S Bullich","year":"2021","unstructured":"Bullich S, Ro\u00e9-Vellv\u00e9 N, Marqui\u00e9 M, Landau SM, Barthel H, Villemagne VL, et al. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021;13:1\u201315.","journal-title":"Alzheimers Res Ther"},{"key":"2051_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40478-016-0399-z","volume":"4","author":"MD Ikonomovic","year":"2016","unstructured":"Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, et al. Post-mortem histopathology underlying \u03b2-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016;4:130.","journal-title":"Acta Neuropathol Commun"},{"key":"2051_CR30","doi-asserted-by":"crossref","unstructured":"Collij LE, Bischof GN, Altomare D, Bader I, Battle M, V\u00e1llez Garc\u00eda D, et al. Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study. J Nucl Med. 2024;1\u20137.","DOI":"10.1101\/2024.05.22.24307653"},{"key":"2051_CR31","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","volume":"50","author":"A Jovalekic","year":"2023","unstructured":"Jovalekic A, Ro\u00e9-Vellv\u00e9 N, Koglin N, Quintana ML, Nelson A, Diemling M, et al. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur J Nucl Med Mol Imaging. 2023;50:3276\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2051_CR32","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12149-024-01919-3","volume":"38","author":"C Shang","year":"2024","unstructured":"Shang C, Sakurai K, Nihashi T, Arahata Y, Takeda A, Ishii K, et al. Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods. Ann Nucl Med. 2024;38:460\u20137.","journal-title":"Ann Nucl Med"},{"key":"2051_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12149-024-01955-z","volume":"38","author":"R Yamakuni","year":"2024","unstructured":"Yamakuni R, Murakami T, Ukon N, Kakamu T, Toda W, Hattori K, et al. Differential centiloid scale normalization techniques: comparison between hybrid PET\/MRI and independently acquired MRI. Ann Nucl Med. 2024;38:835\u201346.","journal-title":"Ann Nucl Med"},{"key":"2051_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clinph.2023.12.131","volume":"158","author":"T Murakami","year":"2024","unstructured":"Murakami T, Abe M, Tiksnadi A, Nemoto A, Futamura M, Yamakuni R, et al. Abnormal motor cortical plasticity as a useful neurophysiological biomarker for Alzheimer\u2019s disease pathology. Clin Neurophysiol. 2024;158:170\u20139.","journal-title":"Clin Neurophysiol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02051-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:12:31Z","timestamp":1757167951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02051-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2051"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02051-6","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This cross-sectional retrospective study was approved by the institutional ethics committee. The requirement for written informed consent was waived due to data anonymization and the study\u2019s retrospective nature. Opt-out methods for participants were provided by publishing a study summary on institutional websites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Research Ethics Committee of Fukushima Medical University (file number: REC2023-137, RK2019-004). This study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its subsequent amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}